"tVNS therapy in Comatose Patients"  has been a focus research area in recent years in collaboration with esteemed scientists from various countries. The Coma Symposium brought together notable experts, including Prof. Dr. Halil Özcan, Head of the Psychiatry Department at Erzurum Atatürk University, Prof. Dr. Arshad Majid, Head of Neuroscience and Cerebrovascular Neurology at the University of Sheffield, UK, Prof. Armin Bolz, the scientist who has been developing of the patented tVNS technology from Germany, and Selin Erdoğan Gezen, Global Clinical Director at tVNS Health Gmbh. The symposium hosted the discussions on the use of tVNS in comatose patients, sharing clinical experiences, and exploring the future of this therapy. The meeting was held on November 14-15th, under the organization of the Akogo Foundation, committed to providing care at the highest international standards, employing advanced diagnostic tools and neurorehabilitation techniques, in two dedicated "Alarm Clock" Clinics, the first rehabilitation centers for children and adults, in Poland. The event was a highly productive scientific meeting where the use of tVNS in comatose patients across different countries was discussed, patient grou ps who has the potential to benefit from the therapy were identified, and future scientific collaborations and studies were initiated. Sessions also featured case reports from Turkey by esteemed doctors Assoc. Prof. Dr. Burcu Polat and Prof. Dr. Ercan Gürses , highlighting treatments applied to hypoxic patients. These sessions provided inspiration for future treatment protocols. In the coming days, we look forward to sharing the results of a clinical study on the application of tVNS therapy, with the hope that it will inspire and bring new possibilities. We remain committed to offering hope to patients considered untreatable through non-invasive, scientifically supported therapies. Our deepest gratitude goes to our esteemed doctors and scientists for their invaluable contributions to these efforts. A special thank you to Fundacja Ewy Błaszczyk Akogo? for hosting this impactful event and fostering collaboration to advance pediatric care. Together, we’re working towards brighter possibilities. Source: https://www.akogo.pl/pl/aktualnosci/budzik-dla-dzieci/nauka-nie-spi #coma #tvns #vagusnerve #vagusnervestimulation #vnstherapy #vagusnerve #comatose #akogo #stroke #stroketreatment

Zeliha Korkmaz, the mother of 7-year-old Oğuzhan, who battles resistant epilepsy and was diagnosed with Dravet syndrome at 4.5 months old, recently shared their transformative journey with tVNS. Oğuzhan endured numerous hospitalizations due to refractory seizures, even undergoing a ketogenic diet that eventually proved ineffective. Following his physician's recommendation, Oğuzhan began using tVNS in January 2022. Since then, the positive impact on his life has been remarkable — experiencing extended seizure-free periods, enhanced cognitive abilities, and an overall improved quality of life. At tVNS, we strive to contribute to a better world for human life by evolving treatments to meet the changing needs of our dynamic world.

The "tVNS Special Issue", has been published in the "Journal Autonomic Neuroscience", the official journal of the International Society for Autonomic Neuroscience, published by Elsevier. We are proud to design the future of neuroscience and to be the pioneer of the medical technologies. Below are the titles of the tVNS Clinical Studies and articles in the journal. Link is below: 1. tVNS in the treatment of drug-resistant epilepsy 2. Cardiovascular responses to low-level transcutaneous vagus nerve stimulation 3. Electrical vagus nerve stimulation as a prophylaxis for SIRS and postoperative ileus 4. tVNS as a potential therapeutic application for neurodegenerative disorders – A focus on dysautonomia in Parkinson's disease 5. tVNS in the management of headache and pain 6. Brain plasticity and vagus nerve stimulation 7. tVNS for the treatment of postural tachycardia syndrome 8. Functional anatomy of the vagus system – Emphasis on the somato-visceral interface 9. Effects of tVNS on cardiovascular autonomic control in health and disease 10. tVNS and heart rate variability: Analysis of parameters and targets 11. Current challenges in reliably targeting the noradrenergic locus coeruleus using transcutaneous auricular vagus nerve stimulation (taVNS) 12. The LC-NE system as a potential target for neuromodulation to ameliorate non-motor symptoms in Parkinson's disease 13. Vagus nerve afferent stimulation: Projection into the brain, reflexive physiological, perceptual, and behavioral responses, and clinical relevance 14. Transcutaneous vagus nerve stimulation (tVNS) in stroke: the evidence, challenges and future directions 15. t-VNS to treat disorders of behaviour in Prader-Willi Syndrome and in people with other neurodevelopmental conditions 16. Technical aspects and future approaches in transcutaneous vagus nerve stimulation (tVNS) 17. A two-week course of transcutaneous vagal nerve stimulation improves global sleep: Findings from a randomised trial in community-dwelling adults https://www.sciencedirect.com/journal/autonomic-neuroscience/special-issue/10DBND1B8HC

< Back Best smart wearables of 2023 Sean Michaels Mar 22, 2023 This is placeholder text. To change this content, double-click on the element and click Change Content. This is placeholder text. To change this content, double-click on the element and click Change Content. Want to view and manage all your collections? Click on the Content Manager button in the Add panel on the left. Here, you can make changes to your content, add new fields, create dynamic pages and more. Your collection is already set up for you with fields and content. Add your own content or import it from a CSV file. Add fields for any type of content you want to display, such as rich text, images, and videos. Be sure to click Sync after making changes in a collection, so visitors can see your newest content on your live site. Previous Next

TVNS treatment in Crohn's disease. The most up-to-date health information on crohn's disease causes, symptoms, treatment options Crohn's Disease Groundbreaking Technologies for Life What is Crohn's Disease ? Crohn's disease is a type of inflammatory bowel disease that causes inflammation of the gastrointestinal tract from the mouth to the anus. This inflammation can be attached to one or more parts of the digestive system, but it is usually seen in the ileum, which is the last part of the small intestine, and in the beginning of the large intestine. Crohn's disease can cause inflammation in your digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Growth-development retardation in children may be signs of Crohn's disease. Extra-intestinal diseases are also observed in a quarter of Crohn's patients. These mostly occur in the skin, joints, eyes, liver and biliary tract, kidney and urinary tract, vascular heart and lungs. Crohn's Disease Symptoms Diarrhea Abdominal pains Intestinal blockages Fever Fatigue Loss of appetite and weight loss Still feeling full after using the toilet Frequent toileting is one of the early symptoms of Crohn's disease. Insomnia Tanı Yöntemleri Crohn's Disease Causes Immune system: It is possible for a virus or bacteria to trigger Crohn's disease; however, scientists have yet to identify such a trigger. When your immune system tries to fight off the invading microorganism, an abnormal immune response can cause the immune system to attack cells in the digestive tract as well. Heredity: Crohn's disease is more common in people with a family history of the same disease, so genes may play a role in the occurrence of the disease. Crohn's Disease Diagnostic Methods Blood analysis Stool analysis Stomach, small and large intestine films Colonoscopy and endoscopy CT and MRI images Crohn's disease can occur at any age, but it usually occurs when the disease is young. Most people who develop Crohn's disease are diagnosed before they reach the age of about 30. You are at higher risk for the disease if you have a first-degree relative with the disease, such as a parent, sibling, or child. About 1 in 5 people with Crohn's disease have a family member with the disease. Facts About Crohn's Disease Treatment Options for Crohn's Disease Medication Steroid drugs: These are drugs to reduce inflammation in the digestive system. Drugs for the immune system: These are drugs used to control the immune system. More information Surgical treatment Most Crohn's Disease patients may need surgical treatment. Removing the problematic parts of the digestive system and reconnecting them to healthy parts is the aim of surgical treatment. More information Crohn's Disease Diet In general, the patient is given a high-energy, abundant protein, low-fiber, low-fat diet rich in vitamins and minerals. For some patients, consumption of milk and dairy products is prohibited. More information Transcutaneous Vagus Nerve Stimulation (tVNS) tVNS ® reduces inflammation in the intestine, allowing the intestine to do its job more healthily. More information Contact us

tVNS non-surgical tvns treatment for cognitive impairment, dementia and alzheimer's. The most up-to-date health information on cognitive impairment causes, symptoms, and treatment options Cognitive Impairment Groundbreaking Technologies for Life What is Cognitive Impairment? The shrinkage caused by the loss of cells in the brain causes various functional disorders. These dysfunctions may manifest as dementia, Alzheimer, and mild cognitive impairment, which are comm on in people ives. People with cognitive impairment are at high risk for Alzheimer and dementia. When adequate precautions are taken, cognitive impairment may regress, and it is possible for these people to lead a normal life. Types of Cognitive Disorder Demantia It is the inadequacies experienced in language, skills and orientation, especially forgetfulness. Dementia is a family that includes many different types. There are Alzheimer's, dementia due to c hronic cerebrovascular disease, alcoholic dementia, depr essive dementia, dementia due to infections, etc. Dementia occurs as a result of general deterioration of the upper level functions of the cerebral cortex, especially over 75 years of age, with advancing age. There are dementias that start with memory impairment such as Alzheimer's disease, as well as behavioral disorders, skill disorders, depression, There are also dementias that start with the symptoms of parkinson's disease and language disorders. It is a progressive disease. Alzhemeir It is the most common type of dementia is a neurological disease that causes the destruction of brain cells. The disease, which causes a decrease in thought, memory and behavioral functions, occurs after a long time with advancing age. It may take years for the disease to reach advanced stages. Because it is a progressive disease, Alzheimer's patients experience problems such as inability to perform their daily tasks, forgetfulness and serious confusion. People with memory loss or other possible Alzheimer's symptoms may have trouble recognizing that they have a problem. Treatment Options for Cognitive Disorder There is no drug therapy approved to treat cognitive impairment. Medicines used to treat symptoms of Alzheimer's disease have been tried. Some studies have found that using these drugs for cognitive impairment is helpful, while others have concluded that there is no benefit. It has been noted that the use of other drugs, including NSAIDs, Ginkgo, Biloba and vitamin E, does not provide a great benefit. tVNS Effect Mechanism There are many clinical studies in recent years that cognitive disorders are caused by inflammation in the brain. Although the basic efficacy mechanism of tVNS has not been fully resolved, our new generation devices in 2021 became the first neuromodulation therapy approved for cognitive impairment in the world, due to both its benefits in the treatment of inflammation and the increase in neuroplasticity. Contact us